Search results
Showing 586 to 600 of 600 results for women's health
NICE publishes final guideline advising on care throughout a woman's pregnancy
The updated antenatal care guideline focuses on women-centred care, informed shared decision making and the role of partners during pregnancy.
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
NICE seeks to support new mothers with mental health problems
NICE is calling on general practice staff to assess the mental health of all women who have recently given birth, as fears some may be left unsupported.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
NICE is delighted with today’s (15 March) announcement from the Department of Health & Social Care appointing six new non-executive directors to its Board following their approval by the Secretary of State.
Improving the uptake of hepatitis B vaccination among at risk groups, developing tools to make evidence-based medicine more accessible, and carrying out a clinical outcome assessment in hand surgery are just some of the projects planned by the latest group of fellows and scholars.
Wireless device recommended for treating people with overactive bladder
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.
Price discount helps give green light for breast cancer drug pertuzumab
NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink tumours in some people with breast cancer so surgery can take place.
The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access has been recommended for routine use in the NHS by NICE in final draft guidance published today (24 February).
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
Patients with blood clots should be treated within 4 hours, says NICE
People who present to hospital with blood clots in the legs or lungs should be offered treatment within 4 hours and have their investigative tests including scans within 24 hours, according to latest guidelines.
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE today (26 February) recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
where appropriate offer statins to people at risk. Menopause Most women experience some symptoms with menopause. The depletion of...